How to Invalidate a European Patent: EPO Opposition, UK Revocation & Clearing Freedom-to-operate (2026)

Understanding how to invalidate a European patent is critical for any life-sciences company that needs to clear a path for a biosimilar launch, protect a diagnostics platform, or resolve a freedom-to-operate conflict in the United Kingdom or across Europe. Two principal routes exist, filing an EPO opposition at the European Patent Office within the strict nine-month window, or pursuing patent revocation UK procedures through the UKIPO or the Patents Court, and the right choice depends on timing, geography, cost appetite, and the nature of the prior art available.

This guide, updated to 19 May 2026, integrates the EPO procedural updates that took effect on 1 January 2026, the UKIPO fee increases and One IPO digital service rollout from 1 April 2026, and practical evidence strategies drawn from extensive EPO hearing experience in biologics and diagnostics cases.

TL;DR, Quick Answers and Who This Guide Is For

Before diving into the detail, here are the headline points for in-house counsel, IP managers, and commercial teams evaluating how to invalidate a European patent in 2026:

• Central route (EPO opposition). File within 9 months of the mention of grant in the European Patent Bulletin. A successful opposition revokes the patent across all designated Contracting States, the most cost-effective option when multiple markets are at stake.
• National route (UK revocation). No fixed filing window. Apply to the UKIPO for a validity opinion, file a revocation action at the UKIPO, or bring proceedings before the Patents Court. Affects only the UK part of the European patent.
• 2026 fee and process changes. The UKIPO fee increase 2026 (effective 1 April 2026) raised several official fees for patent applications and requests. The One IPO patent service now provides a single digital filing and management portal. EPO procedural updates from 1 January 2026 have adjusted post-grant workflow timelines.
• Life-sciences focus. Biologics, diagnostics, and therapeutic-protein cases demand specialised evidence, sequence listings, deposited material data, clinical-trial disclosures, and a deep understanding of EPO sufficiency standards and UK claim-construction principles.
• Act fast. If you are inside the nine-month EPO opposition window, assess central opposition first. If the window has closed, pivot to the national route or consider limitation proceedings at the EPO.

This guide is written for IP managers, in-house counsel at biotech and pharmaceutical companies, R&D commercial teams clearing freedom to operate UK pathways, and litigators preparing validity challenges. It provides actionable checklists, a decision tree, a comparison table, and a 30/60/90-day action plan.

What Is a European Patent and Is It Valid in the UK?

How Validation and Territorial Effect Work

A European patent is not a single unitary right that automatically covers the entire continent. It is granted centrally by the European Patent Office under the European Patent Convention (EPC), but it takes effect as a bundle of national patents, one for each Contracting State in which the proprietor validates the grant by paying the required national fees and, where necessary, filing translations. The result is that a European patent designating the United Kingdom creates a “UK part” that is enforceable as if it were a patent granted under the UK Patents Act 1977. Section 77 of the Act, as explained in the UKIPO Manual of Patent Practice, governs this effect.

UK Effect Post-Brexit

Following Brexit, the UK is no longer an EU Member State, but it remains a Contracting State to the EPC. European patents designating the UK continue to be validated and enforced in the UK in exactly the same way as before. The key practical consequence is that the UK is outside the jurisdiction of the Unified Patent Court (UPC), so any decision to revoke the UK part of a European patent must be pursued either centrally at the EPO (during opposition) or nationally via the UKIPO or UK courts. For a biologics company, this means a successful EPO opposition still revokes the UK designation, but a UPC revocation action would not affect the UK part at all.

Quick Decision Tree: When to Use EPO Opposition vs UK Revocation

Deciding how to invalidate a European patent starts with three tactical questions: How long ago was the patent granted? Which geographic markets matter? And what is the budget?

Key Tactical Factors

• Time since grant. If fewer than 9 months have elapsed since the mention of grant in the European Patent Bulletin, EPO opposition is available and almost always preferable for multi-jurisdictional clearance.
• Markets covered. If only the UK market matters, a national revocation action may be faster and more targeted. If the patent is validated in Germany, France, the Netherlands, and the UK, central opposition clears all four designations in a single proceeding.
• Cost sensitivity. EPO opposition involves a fixed official fee plus professional costs for evidence preparation and representation. UK Patents Court litigation is typically significantly more expensive, though a UKIPO validity opinion is relatively low-cost.
• Desired scope of revocation. Central opposition can result in full revocation, partial revocation (amended claims), or maintenance as granted. National revocation affects only the UK part.

Three Biotech Scenarios

Scenario 1, Biosimilar launch across Europe. A biosimilar manufacturer identifies a blocking patent granted 4 months ago, validated in 12 states including the UK. The optimal route is to oppose the European patent centrally at the EPO, attacking novelty and sufficiency. A single proceeding can clear all 12 markets.

Scenario 2, UK-only diagnostics platform. A diagnostics company discovers a European patent that was granted 18 months ago. The EPO opposition window has closed. The company’s only commercial interest is the UK. The right step is to file for patent revocation UK, either through a UKIPO opinion request followed by a revocation application, or directly before the Patents Court if an injunction is threatened.

Scenario 3, Dual-track clearance. A therapeutic-protein developer is inside the 9-month window but faces an imminent UK infringement threat. Industry observers expect that a dual-track strategy, filing EPO opposition while simultaneously seeking an expedited UK Patents Court declaration of invalidity, offers the strongest protection, albeit at higher cost.

How to Invalidate a European Patent via EPO Opposition: Step-by-Step

Who Can File and Standing

Any person can file an opposition against a European patent, there is no requirement to demonstrate a commercial interest or to be a competitor. The only exception is the patent proprietor itself. Oppositions can be filed by individuals, companies, trade associations, or even anonymously through a professional representative (straw-man oppositions), although the latter raises tactical considerations about credibility at oral proceedings.

The 9-Month Deadline

The opposition period opens on the date the mention of grant of the European patent is published in the European Patent Bulletin and runs for exactly 9 months. This deadline is absolute and cannot be extended. Missing it forecloses the central EPO opposition route entirely. For life-sciences companies monitoring patent landscapes, this means grant-watching systems must be configured to flag relevant publications immediately. The deadline is governed by Rule 76(1) EPC, and the EPO Oppositions page provides the definitive procedural reference.

Filing Requirements

An opposition is filed using EPO Form 2300 and must include:

• Identification of the patent. Publication number and proprietor details.
• Extent of opposition. Whether the entire patent or specific claims are challenged.
• Grounds of opposition. At least one ground under Article 100 EPC: (a) lack of novelty or inventive step (Article 52–56 EPC); (b) insufficiency of disclosure (Article 83 EPC); or (c) added matter, the patent extends beyond the content of the application as filed (Article 123(2) EPC).
• Statement of facts and evidence. Prior-art documents, clinical-trial publications, conference posters, deposited sequence listings, or any other evidence supporting the grounds.
• Opposition fee. The official EPO opposition fee must be paid within the 9-month period.

Evidence Types for Life Sciences

In biologics and diagnostics oppositions, the evidence portfolio typically includes:

• Published prior art. Scientific journal articles, patent-family documents, WHO INN publications, and pharmacopoeia monographs predating the priority date.
• Clinical-trial disclosures. ClinicalTrials.gov entries, EMA assessment reports, and FDA Biologics License Application (BLA) summaries that disclose key structural or functional features of the claimed invention.
• Deposited biological material. Data from culture-collection accession records (e.g., ATCC, DSMZ) confirming availability and characteristics of deposited strains or cell lines.
• Sequence listings. GenBank or UniProt records showing prior disclosure of nucleotide or amino-acid sequences claimed in the patent.
• Expert declarations. Written opinions from specialists in the relevant technical field addressing common general knowledge and whether the skilled person would have arrived at the claimed invention.

EPO Opposition Timeline

The following table reflects typical durations based on EPO practice. Actual timelines vary depending on the complexity of the case, number of opponents, and whether oral proceedings are requested.

The total EPO opposition timeline from filing to first-instance decision is typically 12–30 months. If an appeal is filed, the entire process can extend to 4–6 years. Early indications suggest that EPO procedural updates from January 2026 are beginning to accelerate written-phase management, but oral-hearing scheduling remains capacity-dependent.

Revoking the UK Part: National Route and UKIPO Procedures

UKIPO Validity Opinions and Revocation Requests

If the EPO opposition window has closed, or if a challenger’s sole interest is the UK market, it is possible to revoke the UK part of a European patent through national procedures. The UKIPO offers two key tools:

• Validity opinion. Under Section 74A of the Patents Act 1977, any person may request a non-binding opinion from the UKIPO on whether a patent is valid. This is a low-cost, relatively fast route (typically 3–6 months) to obtain an authoritative assessment. While the opinion is not legally binding, it carries persuasive weight and can inform licensing negotiations or decisions to proceed with formal revocation.
• Revocation application. Under Section 72 of the Patents Act 1977, any person may apply to the UKIPO Comptroller for revocation of a patent on grounds including lack of novelty, lack of inventive step, insufficiency, added matter, or that the patent was granted to a person not entitled. The Comptroller can revoke the UK part of the European patent, but the decision affects only UK rights.

UK Court Revocation Actions (Patents Court)

For higher-stakes disputes, particularly where an injunction is threatened or damages claims are in play, revocation can be pursued before the Patents Court (part of the High Court of England and Wales). Court proceedings offer broader procedural tools including disclosure, cross-examination, and the possibility of expedited trials. For biologics cases, UK courts apply a purposive claim-construction approach that can produce different outcomes from EPO claim interpretation, particularly for second-medical-use claims and dosage-regime patents. The likely practical effect is that in-house teams must weigh the cost of full litigation (often six figures in legal fees) against the strategic value of a binding UK court judgment that cannot be appealed at the EPO level.

One IPO Digital Service and UKIPO Fee Changes (1 April 2026)

The UKIPO’s One IPO patent service, rolled out progressively through 2025–2026, consolidates patent filings, renewals, and requests into a single digital platform. From 1 April 2026, revised official fees apply to patent applications and certain post-grant requests, including validity-opinion fees and revocation application fees. The UKIPO fee increase 2026 is part of a broader cost-recovery programme announced by the Intellectual Property Office. Industry observers expect the fee changes to have a modest impact on overall challenge costs, but they should be factored into budget planning, particularly for portfolio-level freedom-to-operate clearance programmes that involve multiple validity opinions.

Comparative Table: EPO Opposition vs UK Revocation

The following table summarises the key differences between the two principal routes for invalidating a European patent, with considerations specific to life-sciences disputes.

Costs, Fees (2026 Updates), and Commercial Impact on Freedom-to-Operate

EPO Opposition Costs

The official EPO opposition fee is a fixed amount payable at filing. On top of this, professional representative costs include prior-art searching, evidence compilation (particularly important for biologics cases involving sequence analysis and expert declarations), drafting the notice of opposition and written submissions, and attendance at oral proceedings. Total costs for a single-opponent, first-instance EPO opposition in a biotech case typically range from the mid-five figures to the low-six figures (in GBP), depending on complexity. These are estimates, costs vary significantly based on the number of prior-art documents, the need for expert witnesses, and the length of the written phase. Challengers should always obtain a case-specific fee estimate from qualified counsel.

UKIPO Fees and the April 2026 Increase

Under the UKIPO fee increase 2026, official fees for validity opinions, revocation applications, and certain renewal and search fees were revised upward from 1 April 2026. While official fees remain modest relative to overall project costs, the cumulative impact matters for companies running portfolio-level clearance programmes across multiple patents. Court costs for Patents Court proceedings are substantially higher and include court fees, counsel fees, expert-witness costs, and disclosure management. An expedited trial in the Patents Court can cost well into six figures.

Commercial Considerations: Freedom to Operate UK

For life-sciences companies, invalidating a blocking patent is often part of a broader freedom to operate UK clearance strategy. The commercial stakes include:

• Injunction risk. If the patent is upheld, the proprietor may obtain an injunction preventing launch, supply, or import. Clearing the patent pre-launch eliminates this risk.
• Supply continuity. For biologics with long manufacturing lead times, a revocation or opposition should be initiated well before planned regulatory approval to avoid product delays.
• Licensing alternatives. Where invalidity arguments are strong but not certain, a licence-first strategy (with a challenge clause) may provide commercial certainty while preserving the right to challenge.
• Enforcement risk matrix. Map each blocking patent against launch markets, expiry dates, and supplementary-protection-certificate (SPC) timelines to prioritise challenges.

Evidence Checklist and Practitioner Tips for Biologics and Diagnostics

Evidence Types

Building a winning evidence package to oppose a European patent in the life-sciences space requires methodical preparation. The following checklist covers the most common evidence categories:

• Published prior art. Journal articles, conference posters, and abstracts, check publication dates carefully against the priority date.
• Patent family analysis. Earlier filings in the same family may disclose subject matter that destroys novelty or provides an obvious starting point for inventive-step attacks.
• Clinical-trial database entries. ClinicalTrials.gov and EU Clinical Trials Register entries often disclose dosage regimes, formulations, and patient populations before the priority date.
• Sequence and structural data. GenBank, UniProt, and PDB entries documenting prior disclosure of sequences or protein structures.
• Regulatory filings. EMA and FDA assessment reports (published after authorisation) can evidence prior disclosure of specific biological mechanisms.
• Expert declarations. Commissioned statements from independent scientists confirming common general knowledge and the expectations of the skilled person.

Drafting Strategy: Attack Claims vs Attack Priority Chain

Two principal attack vectors exist when preparing to oppose a European patent. The first is a direct attack on the claims, arguing that the claims as granted lack novelty or inventive step over identified prior art. The second is an attack on the priority chain, arguing that the claims are not entitled to the claimed priority date because the priority document does not disclose the same invention. If the priority date is successfully challenged, additional prior art falling between the priority date and the filing date becomes available. In biotech cases, priority attacks are particularly powerful where the priority application describes a broad genus but the granted claims cover a specific antibody, sequence, or formulation that was not individually disclosed.

Preparing for Oral Proceedings: Common EPO Pitfalls in Biotech

Oral proceedings before the EPO Opposition Division are the decisive stage in most contested oppositions. Common pitfalls to avoid include:

• Late-filed evidence. The Opposition Division has discretion to refuse late-filed documents. File all key evidence with the notice of opposition or at the earliest opportunity.
• Overly broad attacks. Focus on the two or three strongest arguments rather than presenting a scattergun of weak points. The Division has limited time and responds better to clear, focused reasoning.
• Underestimating sufficiency. In biotech cases, sufficiency of disclosure (Article 83 EPC) is often a decisive ground. Prepare experimental evidence or expert testimony showing that the skilled person could not reproduce the claimed invention across its full scope without undue burden.
• Ignoring auxiliary requests. Proprietors routinely file multiple sets of auxiliary (fallback) claims. Prepare counterarguments for each auxiliary request in advance of the hearing, not on the day.
• Failure to rehearse. Oral proceedings are semi-formal but highly interactive. Rehearsal, including practising responses to unexpected questions from the Division, significantly improves hearing performance.

After the Decision: Appeals, Limitation, National Enforcement and Settlements

Effect of a Successful EPO Opposition

If the Opposition Division revokes the European patent, the revocation takes effect retroactively across all designated Contracting States once the decision becomes final (i.e., when the appeal period expires without an appeal being filed, or when the Board of Appeal upholds the revocation). The UK part of the patent ceases to have effect under Section 77 of the Patents Act 1977. If the patent is maintained in amended form, the amended claims take effect nationally, subject to any translation requirements.

Appeals, Limitation, and Settlement Options

Either party may appeal the Opposition Division’s decision to the EPO Boards of Appeal. Appeals add 24–48 months to the overall timeline. As an alternative to full revocation, the patent proprietor may file a request for limitation under Article 105a EPC, voluntarily narrowing the claims to avoid the contested prior art. From the challenger’s perspective, settlement options include negotiated licence agreements, consent revocations (where the proprietor voluntarily surrenders the patent), or coexistence agreements defining field-of-use restrictions.

Practical Next Steps: 30/60/90-Day Action Plan

The following timeline provides an actionable framework for in-house teams preparing to challenge or clear freedom-to-operate against a European patent in the UK.

1. Days 1–30: Assessment and evidence gathering. Confirm the grant date and calculate the EPO opposition deadline. Commission a prior-art search targeting novelty, inventive step, and sufficiency grounds. Assemble clinical-trial disclosures, sequence data, and relevant patent-family documents. Obtain an initial cost estimate from qualified patent counsel.
2. Days 31–60: Strategy selection and filing preparation. Decide between EPO opposition, UK revocation, or dual-track. Draft the notice of opposition (if within the 9-month window) or the UKIPO revocation application. Commission expert declarations. Finalise the evidence package and budget.
3. Days 61–90: Filing and engagement. File the opposition or revocation application. Pay all official fees. Notify internal stakeholders (regulatory, commercial, manufacturing) of anticipated timelines. Begin preparing for written-phase submissions and, if EPO opposition, anticipate the proprietor’s response.

When to instruct counsel: If a blocking patent has been identified and a product launch is planned within 24 months, instruct specialist patent counsel immediately, ideally before the end of Day 10. The 9-month EPO opposition window is an absolute cut-off, and evidence preparation for biologics cases typically requires 4–8 weeks of lead time.

Sources

1. European Patent Office, Oppositions
2. EPO, Article 138 EPC (Revocation of European Patents)
3. EPO, Guide to the EPC: Limitation and Revocation
4. GOV.UK, Manual of Patent Practice: Section 77 (Effect of European Patent UK)
5. UKIPO, Intellectual Property Office (One IPO and Fee Schedule)
6. Managing IP
7. IAM Media
8. WIPO, World Intellectual Property Organization